inaccurate article sends cytrx shares lower $0.01 web...
TRANSCRIPT
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 16
SUBSCRIBER LOGIN
Trending 5 of Americarsquos Favorite Automotive Brands (408
PM)
Follow 223K followers
$001 Web Hostingwwwhostgatorcom1Penny
Get Your First Month for 1 Cent Try Our AwardshyWinning Service Now
STOCK NEWS INVESTING IDEAS ECON amp POLICY PERSONAL FINANCE TOOLS FOR INVESTORS Search Quotes or News
35kLike
HOME EXPERT
Inaccurate Article Sends CytRx Shares Lower
CytRx Corporation (NASDAQCYTR) shares have surged highersince last week because of positive data from the companyrsquosPhase 2b first-line soft tissue sarcoma trial The company reportedstatistically significant results and demonstrated 80 to 100 percent
TOM MEYER | MORE ARTICLESDECEMBER 18 2013
Page 1 of 3view all
Advertisement
Advertisement
Trade with TradeStation shy Tradecommissionshyfree for 90 days More
Advertisement
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 26
superiority over doxorubicin in progression-free survival Theresults also showed that aldoxorubicin had a higher overallresponse rate than the current standard of care doxorubicin
Shares of CytRx traded as high as $679 last week before closingthe week at $572 a gain of roughly 150 percent from whereshares began on Monday December 9 Unfortunately aninaccurate report was published on Monday December 16 by TheStreetrsquos Adam Feuerstein The report contained severalinaccuracies which caused shares of CytRx to sell off by morethan 10 percent Mr Feuerstein raised three points that need to beaddressed
Option Grants before Aldoxorubicin Press ReleaseCompared CytRx data to that of Ziopharm Oncology (NASDAQZIOP)Geographic Distribution
The Streetrsquos article seemed to imply that CytRx managementpurposely issued option grants to insiders knowing that a pressrelease would cause the shares to spike shortly after That isinaccurate The CytRx board meets at least once per quarterAdditionally the company has demonstrated a history ofconducting board meetings in December and issuing option grantsduring those same December meetings
In fact just last year CytRx had a board meeting and optionissuance on December 10 and there was no dramatic spike inprice after that issuance It had long been expected that Phase 2bdata would be reported in December 2013 as per the companyrsquostimeline that has been kept up to date on the company websiteThere were also several articles written by various bloggers thatcontinued to mention that Phase 2b data would be reported nearyear-end If the option grants would have been given after theshares spiked with a low option strike there would have been asmuch if not more criticism Itrsquos also important to note that none ofthe board members have ever exercised their options That speaksto their long-term view on the stock and the significant marketpotential that aldoxorubicin has
BROKER PARTNERS
4 Biggest Box OfficeSurprises in January
10 Cars and TrucksThat Survived thePolar Vortex
Celebrity DeathsHighlight StarkReality Heroin Use
Is Surging
3 Less-Known Waysto Contribute to aRoth IRA
Obama Businessand Minimum WageIs It Time For a
STORIES YOULL LOVE
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 36
by TaboolaSponsored Content
Page 1 of 3view all
1 Top 5 Stocks to Buy
2 Best Stocks to Buy
3 High Dividend Paying
4 10 Best Mutual Funds
5 Top 5 Retirement Funds
6 Top Dividend Growth
YOU MAY ALSO LIKE
The New Diet Pill That Has Doctors RavingAll Consumer Health Tips
Truth About AnnuitiesSenior Annuity Alert
20 Celebrities Who Shockingly Used To Be HotAnswers
Homeowners Are In For A Big SurprisehellipSmart Life Weekly
Actress Has Wardrobe Malfunction So Bad You Wont Believe It (PHOTO)Tasty Articles
You Wont Believe Whos Related to Abraham LincolnAncestrycom
Donrsquot know Spanish See this video (Shocking)Pimleur Approach
Check Out These Celebrity Bikini BodiesMyDailyMoment
Raise
MORE MOST POPULAR raquo
Advertisement
Advertisement
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 46
Enter email address Click Here Its Free
The Death of the PCThe days of paying for costly software upgrades are numbered The PC will soon beobsolete And BusinessWeek reports 70 of Americans are already using thetechnology that will replace it Merrill Lynch calls it a $160 billion opportunityComputing giants including IBM Yahoo and Amazon are racing to be the first to cashin on this PCshykilling revolution Yet a small group of littleshyknown companies have a hugehead start Get the full details on these companies and the technology that is destroyingthe PC in a free video from The Motley Fool Enter your email address below to viewthis stunning video
The Motley Fool Terms And Conditions
Wall St Cheat Sheet Privacy Policy
More Articles About CytRx Corporation NASDAQCYTR
Threshold Pharmaceuticals ZIOPHARM Oncology
To contact the reporter on this storystaffwriterswallstcheatsheetcomTo contact the editor responsible for this storyeditorswallstcheatsheetcom
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 56
Wall St Cheat Sheet has been featured in these fine media outlets
Add a comment8 comments
singaporetiger (signed in using yahoo)The AF analysis is even worse than reported in this article (its apples tooranges comparison) In the Ziopharm Picasso III trial patients were excludedif they ever received an anthracycline (including Dox) in any adjuvant orneoadjuvant setting In the CYTR trial patients were allowed to have usedDox in the adjuvant and neoadjuvant setting meaning that some patients hadsurgery then Dox and the tumor grew back with mets These patients areunlikely to respond to Dox compared to patients that were truly naive to Doxsuch as in the Ziopharm Phase III Therefore one would expect a lower PFSand a lower clinical response rate in the CYTR study compared to theZiopharm phase III trial There is nothing inconsistent with the CYTR dataReply middot middot Like middot Follow Post middot December 18 2013 at 705am1
me (signed in using yahoo)Wow you just crushed Feuerstein Great job Hate that guyReply middot middot Like middot Follow Post middot December 18 2013 at 650am1
Nir Etkovitz middot תיכון אחד העםthank you for your interesting articleReply middot middot Like middot Follow Post middot December 18 2013 at 1105am1
backofthebusnj (signed in using yahoo)Feuerstein is Jimmy Crammers butt buddy They both lie to manipulate stockprices for their pals on wall streetReply middot Like middot Follow Post middot Edited middot December 19 2013 at 241pm
tomsilver200 (signed in using yahoo)Cytrx is in on-going discussions with big pharma about partnershiphellipReply middot Like middot Follow Post middot December 18 2013 at 440pm
Login
About Us
Customer Support
Contact Us
Jobs
Affiliates
Archive
Legal Disclaimer
Policy
Google+
STOCK INVESTOR CHEAT SHEET
GOLD amp SILVER INVESTMENTNEWSLETTER
COMMODITIES INVESTMENT NEWSLETTER
WEEKLY STOCK CHEAT SHEETS
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 66
MARKET OUTLOOK 2013
copy amp reg 2013 Wall St Cheat Sheet AllRights Reserved
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 26
superiority over doxorubicin in progression-free survival Theresults also showed that aldoxorubicin had a higher overallresponse rate than the current standard of care doxorubicin
Shares of CytRx traded as high as $679 last week before closingthe week at $572 a gain of roughly 150 percent from whereshares began on Monday December 9 Unfortunately aninaccurate report was published on Monday December 16 by TheStreetrsquos Adam Feuerstein The report contained severalinaccuracies which caused shares of CytRx to sell off by morethan 10 percent Mr Feuerstein raised three points that need to beaddressed
Option Grants before Aldoxorubicin Press ReleaseCompared CytRx data to that of Ziopharm Oncology (NASDAQZIOP)Geographic Distribution
The Streetrsquos article seemed to imply that CytRx managementpurposely issued option grants to insiders knowing that a pressrelease would cause the shares to spike shortly after That isinaccurate The CytRx board meets at least once per quarterAdditionally the company has demonstrated a history ofconducting board meetings in December and issuing option grantsduring those same December meetings
In fact just last year CytRx had a board meeting and optionissuance on December 10 and there was no dramatic spike inprice after that issuance It had long been expected that Phase 2bdata would be reported in December 2013 as per the companyrsquostimeline that has been kept up to date on the company websiteThere were also several articles written by various bloggers thatcontinued to mention that Phase 2b data would be reported nearyear-end If the option grants would have been given after theshares spiked with a low option strike there would have been asmuch if not more criticism Itrsquos also important to note that none ofthe board members have ever exercised their options That speaksto their long-term view on the stock and the significant marketpotential that aldoxorubicin has
BROKER PARTNERS
4 Biggest Box OfficeSurprises in January
10 Cars and TrucksThat Survived thePolar Vortex
Celebrity DeathsHighlight StarkReality Heroin Use
Is Surging
3 Less-Known Waysto Contribute to aRoth IRA
Obama Businessand Minimum WageIs It Time For a
STORIES YOULL LOVE
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 36
by TaboolaSponsored Content
Page 1 of 3view all
1 Top 5 Stocks to Buy
2 Best Stocks to Buy
3 High Dividend Paying
4 10 Best Mutual Funds
5 Top 5 Retirement Funds
6 Top Dividend Growth
YOU MAY ALSO LIKE
The New Diet Pill That Has Doctors RavingAll Consumer Health Tips
Truth About AnnuitiesSenior Annuity Alert
20 Celebrities Who Shockingly Used To Be HotAnswers
Homeowners Are In For A Big SurprisehellipSmart Life Weekly
Actress Has Wardrobe Malfunction So Bad You Wont Believe It (PHOTO)Tasty Articles
You Wont Believe Whos Related to Abraham LincolnAncestrycom
Donrsquot know Spanish See this video (Shocking)Pimleur Approach
Check Out These Celebrity Bikini BodiesMyDailyMoment
Raise
MORE MOST POPULAR raquo
Advertisement
Advertisement
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 46
Enter email address Click Here Its Free
The Death of the PCThe days of paying for costly software upgrades are numbered The PC will soon beobsolete And BusinessWeek reports 70 of Americans are already using thetechnology that will replace it Merrill Lynch calls it a $160 billion opportunityComputing giants including IBM Yahoo and Amazon are racing to be the first to cashin on this PCshykilling revolution Yet a small group of littleshyknown companies have a hugehead start Get the full details on these companies and the technology that is destroyingthe PC in a free video from The Motley Fool Enter your email address below to viewthis stunning video
The Motley Fool Terms And Conditions
Wall St Cheat Sheet Privacy Policy
More Articles About CytRx Corporation NASDAQCYTR
Threshold Pharmaceuticals ZIOPHARM Oncology
To contact the reporter on this storystaffwriterswallstcheatsheetcomTo contact the editor responsible for this storyeditorswallstcheatsheetcom
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 56
Wall St Cheat Sheet has been featured in these fine media outlets
Add a comment8 comments
singaporetiger (signed in using yahoo)The AF analysis is even worse than reported in this article (its apples tooranges comparison) In the Ziopharm Picasso III trial patients were excludedif they ever received an anthracycline (including Dox) in any adjuvant orneoadjuvant setting In the CYTR trial patients were allowed to have usedDox in the adjuvant and neoadjuvant setting meaning that some patients hadsurgery then Dox and the tumor grew back with mets These patients areunlikely to respond to Dox compared to patients that were truly naive to Doxsuch as in the Ziopharm Phase III Therefore one would expect a lower PFSand a lower clinical response rate in the CYTR study compared to theZiopharm phase III trial There is nothing inconsistent with the CYTR dataReply middot middot Like middot Follow Post middot December 18 2013 at 705am1
me (signed in using yahoo)Wow you just crushed Feuerstein Great job Hate that guyReply middot middot Like middot Follow Post middot December 18 2013 at 650am1
Nir Etkovitz middot תיכון אחד העםthank you for your interesting articleReply middot middot Like middot Follow Post middot December 18 2013 at 1105am1
backofthebusnj (signed in using yahoo)Feuerstein is Jimmy Crammers butt buddy They both lie to manipulate stockprices for their pals on wall streetReply middot Like middot Follow Post middot Edited middot December 19 2013 at 241pm
tomsilver200 (signed in using yahoo)Cytrx is in on-going discussions with big pharma about partnershiphellipReply middot Like middot Follow Post middot December 18 2013 at 440pm
Login
About Us
Customer Support
Contact Us
Jobs
Affiliates
Archive
Legal Disclaimer
Policy
Google+
STOCK INVESTOR CHEAT SHEET
GOLD amp SILVER INVESTMENTNEWSLETTER
COMMODITIES INVESTMENT NEWSLETTER
WEEKLY STOCK CHEAT SHEETS
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 66
MARKET OUTLOOK 2013
copy amp reg 2013 Wall St Cheat Sheet AllRights Reserved
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 36
by TaboolaSponsored Content
Page 1 of 3view all
1 Top 5 Stocks to Buy
2 Best Stocks to Buy
3 High Dividend Paying
4 10 Best Mutual Funds
5 Top 5 Retirement Funds
6 Top Dividend Growth
YOU MAY ALSO LIKE
The New Diet Pill That Has Doctors RavingAll Consumer Health Tips
Truth About AnnuitiesSenior Annuity Alert
20 Celebrities Who Shockingly Used To Be HotAnswers
Homeowners Are In For A Big SurprisehellipSmart Life Weekly
Actress Has Wardrobe Malfunction So Bad You Wont Believe It (PHOTO)Tasty Articles
You Wont Believe Whos Related to Abraham LincolnAncestrycom
Donrsquot know Spanish See this video (Shocking)Pimleur Approach
Check Out These Celebrity Bikini BodiesMyDailyMoment
Raise
MORE MOST POPULAR raquo
Advertisement
Advertisement
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 46
Enter email address Click Here Its Free
The Death of the PCThe days of paying for costly software upgrades are numbered The PC will soon beobsolete And BusinessWeek reports 70 of Americans are already using thetechnology that will replace it Merrill Lynch calls it a $160 billion opportunityComputing giants including IBM Yahoo and Amazon are racing to be the first to cashin on this PCshykilling revolution Yet a small group of littleshyknown companies have a hugehead start Get the full details on these companies and the technology that is destroyingthe PC in a free video from The Motley Fool Enter your email address below to viewthis stunning video
The Motley Fool Terms And Conditions
Wall St Cheat Sheet Privacy Policy
More Articles About CytRx Corporation NASDAQCYTR
Threshold Pharmaceuticals ZIOPHARM Oncology
To contact the reporter on this storystaffwriterswallstcheatsheetcomTo contact the editor responsible for this storyeditorswallstcheatsheetcom
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 56
Wall St Cheat Sheet has been featured in these fine media outlets
Add a comment8 comments
singaporetiger (signed in using yahoo)The AF analysis is even worse than reported in this article (its apples tooranges comparison) In the Ziopharm Picasso III trial patients were excludedif they ever received an anthracycline (including Dox) in any adjuvant orneoadjuvant setting In the CYTR trial patients were allowed to have usedDox in the adjuvant and neoadjuvant setting meaning that some patients hadsurgery then Dox and the tumor grew back with mets These patients areunlikely to respond to Dox compared to patients that were truly naive to Doxsuch as in the Ziopharm Phase III Therefore one would expect a lower PFSand a lower clinical response rate in the CYTR study compared to theZiopharm phase III trial There is nothing inconsistent with the CYTR dataReply middot middot Like middot Follow Post middot December 18 2013 at 705am1
me (signed in using yahoo)Wow you just crushed Feuerstein Great job Hate that guyReply middot middot Like middot Follow Post middot December 18 2013 at 650am1
Nir Etkovitz middot תיכון אחד העםthank you for your interesting articleReply middot middot Like middot Follow Post middot December 18 2013 at 1105am1
backofthebusnj (signed in using yahoo)Feuerstein is Jimmy Crammers butt buddy They both lie to manipulate stockprices for their pals on wall streetReply middot Like middot Follow Post middot Edited middot December 19 2013 at 241pm
tomsilver200 (signed in using yahoo)Cytrx is in on-going discussions with big pharma about partnershiphellipReply middot Like middot Follow Post middot December 18 2013 at 440pm
Login
About Us
Customer Support
Contact Us
Jobs
Affiliates
Archive
Legal Disclaimer
Policy
Google+
STOCK INVESTOR CHEAT SHEET
GOLD amp SILVER INVESTMENTNEWSLETTER
COMMODITIES INVESTMENT NEWSLETTER
WEEKLY STOCK CHEAT SHEETS
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 66
MARKET OUTLOOK 2013
copy amp reg 2013 Wall St Cheat Sheet AllRights Reserved
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 46
Enter email address Click Here Its Free
The Death of the PCThe days of paying for costly software upgrades are numbered The PC will soon beobsolete And BusinessWeek reports 70 of Americans are already using thetechnology that will replace it Merrill Lynch calls it a $160 billion opportunityComputing giants including IBM Yahoo and Amazon are racing to be the first to cashin on this PCshykilling revolution Yet a small group of littleshyknown companies have a hugehead start Get the full details on these companies and the technology that is destroyingthe PC in a free video from The Motley Fool Enter your email address below to viewthis stunning video
The Motley Fool Terms And Conditions
Wall St Cheat Sheet Privacy Policy
More Articles About CytRx Corporation NASDAQCYTR
Threshold Pharmaceuticals ZIOPHARM Oncology
To contact the reporter on this storystaffwriterswallstcheatsheetcomTo contact the editor responsible for this storyeditorswallstcheatsheetcom
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 56
Wall St Cheat Sheet has been featured in these fine media outlets
Add a comment8 comments
singaporetiger (signed in using yahoo)The AF analysis is even worse than reported in this article (its apples tooranges comparison) In the Ziopharm Picasso III trial patients were excludedif they ever received an anthracycline (including Dox) in any adjuvant orneoadjuvant setting In the CYTR trial patients were allowed to have usedDox in the adjuvant and neoadjuvant setting meaning that some patients hadsurgery then Dox and the tumor grew back with mets These patients areunlikely to respond to Dox compared to patients that were truly naive to Doxsuch as in the Ziopharm Phase III Therefore one would expect a lower PFSand a lower clinical response rate in the CYTR study compared to theZiopharm phase III trial There is nothing inconsistent with the CYTR dataReply middot middot Like middot Follow Post middot December 18 2013 at 705am1
me (signed in using yahoo)Wow you just crushed Feuerstein Great job Hate that guyReply middot middot Like middot Follow Post middot December 18 2013 at 650am1
Nir Etkovitz middot תיכון אחד העםthank you for your interesting articleReply middot middot Like middot Follow Post middot December 18 2013 at 1105am1
backofthebusnj (signed in using yahoo)Feuerstein is Jimmy Crammers butt buddy They both lie to manipulate stockprices for their pals on wall streetReply middot Like middot Follow Post middot Edited middot December 19 2013 at 241pm
tomsilver200 (signed in using yahoo)Cytrx is in on-going discussions with big pharma about partnershiphellipReply middot Like middot Follow Post middot December 18 2013 at 440pm
Login
About Us
Customer Support
Contact Us
Jobs
Affiliates
Archive
Legal Disclaimer
Policy
Google+
STOCK INVESTOR CHEAT SHEET
GOLD amp SILVER INVESTMENTNEWSLETTER
COMMODITIES INVESTMENT NEWSLETTER
WEEKLY STOCK CHEAT SHEETS
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 66
MARKET OUTLOOK 2013
copy amp reg 2013 Wall St Cheat Sheet AllRights Reserved
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 56
Wall St Cheat Sheet has been featured in these fine media outlets
Add a comment8 comments
singaporetiger (signed in using yahoo)The AF analysis is even worse than reported in this article (its apples tooranges comparison) In the Ziopharm Picasso III trial patients were excludedif they ever received an anthracycline (including Dox) in any adjuvant orneoadjuvant setting In the CYTR trial patients were allowed to have usedDox in the adjuvant and neoadjuvant setting meaning that some patients hadsurgery then Dox and the tumor grew back with mets These patients areunlikely to respond to Dox compared to patients that were truly naive to Doxsuch as in the Ziopharm Phase III Therefore one would expect a lower PFSand a lower clinical response rate in the CYTR study compared to theZiopharm phase III trial There is nothing inconsistent with the CYTR dataReply middot middot Like middot Follow Post middot December 18 2013 at 705am1
me (signed in using yahoo)Wow you just crushed Feuerstein Great job Hate that guyReply middot middot Like middot Follow Post middot December 18 2013 at 650am1
Nir Etkovitz middot תיכון אחד העםthank you for your interesting articleReply middot middot Like middot Follow Post middot December 18 2013 at 1105am1
backofthebusnj (signed in using yahoo)Feuerstein is Jimmy Crammers butt buddy They both lie to manipulate stockprices for their pals on wall streetReply middot Like middot Follow Post middot Edited middot December 19 2013 at 241pm
tomsilver200 (signed in using yahoo)Cytrx is in on-going discussions with big pharma about partnershiphellipReply middot Like middot Follow Post middot December 18 2013 at 440pm
Login
About Us
Customer Support
Contact Us
Jobs
Affiliates
Archive
Legal Disclaimer
Policy
Google+
STOCK INVESTOR CHEAT SHEET
GOLD amp SILVER INVESTMENTNEWSLETTER
COMMODITIES INVESTMENT NEWSLETTER
WEEKLY STOCK CHEAT SHEETS
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 66
MARKET OUTLOOK 2013
copy amp reg 2013 Wall St Cheat Sheet AllRights Reserved
252014 Inaccurate Article Sends CytRx Shares Lower
httpwallstcheatsheetcomstocksinaccurate-article-sends-cytrx-shares-lowerhtmlref=YF 66
MARKET OUTLOOK 2013
copy amp reg 2013 Wall St Cheat Sheet AllRights Reserved